Swift Biosciences recently launched myT KRAS, the third product in its myT Primer menu of reagents to detect cancer mutations.

The myT KRAS kit provides 1 percent sensitivity for seven key mutations in codons 12 and 13 with little or no breakthrough from wild type, resulting in an assay with a definitive yes/no answer over a wide dynamic range, Swift said.

The assay works well with both frozen and formalin-fixed, paraffin-embedded samples, and each package includes sufficient reagents to test 30 samples, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.